The Psyence™ Group sets the global standard for natural psychedelics.
Informed by nature and guided by science, Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care.
We are focused on the scientific research and development of psilocybin medical products for research institutions, clinics and regulatory-compliant psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.
Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa.
The Psyence™ Group sets the global standard for natural psychedelics.
Informed by nature and guided by science, Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care.
We are focused on the scientific research and development of psilocybin medical products for research institutions, clinics and regulatory-compliant psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.
Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa.
Psyence is pioneering the use of natural psilocybin for the long-term treatment of trauma and its mental health consequences.
We develop natural psilocybin products,
medicinal formulations and treatment protocols
to treat mental health disorders in a clinical environment.
Learn More
With experience in building disruptive brands and creating
routes to market, we are focused on the development
of over-the-counter proprietary nutraceutical products.
Learn More
We operate one of the first federally licensed commercial
psilocybin cultivation and production facilities in the world.
Learn MorePsyence is pioneering the use of natural psilocybin for the long-term treatment of trauma and its mental health consequences.
Bringing together leaders in the business of medicine and science
Our scientific and medical team, which includes experts in neurology, neuroscience, oncology and drug development, have international expertise in palliative medicine and science. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.
Bringing together leaders in the business of medicine and science
Our scientific and medical team, which includes experts in neurology, neuroscience, oncology and drug development, have international expertise in palliative medicine and science. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.
Our News
Psyence Group Announces DTC Eligibility Approval in the U.S
TORONTO, 09 February 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States (“US”).
Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility
Psyence’s facility, which is federally licensed to cultivate and export psilocybin mushrooms for the legal medical and research markets, is based in Southern Africa and has been operational since January 2021.
Psyence looks to expand capital market opportunities in the UK and Europe
TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.
Our News
Psyence Group Announces DTC Eligibility Approval in the U.S
TORONTO, 09 February 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States (“US”).
Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility
Psyence’s facility, which is federally licensed to cultivate and export psilocybin mushrooms for the legal medical and research markets, is based in Southern Africa and has been operational since January 2021.
Psyence looks to expand capital market opportunities in the UK and Europe
TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.